← Leaderboards

Mary Jackson

Colorado State University

Google Scholar ↗PubMed ↗ORCID ↗

$25,157,631

Attributed

$27,563,125

Total exposure

20

Grants

19

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.8M · FY2007–25

$5M$3.8M$2.5M$1.3M$0

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$27,563,125 · 20

By mechanism

R01$22,771,935 · 8

R21$3,065,845 · 8

RC1$978,779 · 1

R56$667,066 · 1

R03$73,500 · 1

R13$6,000 · 1

Top collaborators

Most similar at Colorado State University

Same institution · by research overlap

Others in their field

Top investigators on “Mycobacterium Tuberculosis”

Margaret Juliana McElrath · Fred Hutchinson Cancer Center$267,251,837
Constance Ann Benson · University Of California, San Diego$150,079,712
Kevin Urdahl · Seattle Children'S Hospital$86,597,961
David Alland · Rutgers Biomedical And Health Sciences$70,943,567
Sarah Fortune · Harvard School Of Public Health$51,119,645
William Robert Jacobs · Albert Einstein College Of Medicine$43,123,310

Research focus

Mycobacterium TuberculosisCellsGeneticMutantStructureGenus MycobacteriumPharmaceutical PreparationsDesignMycobacterialTuberculosisPlayCell EnvelopeBaseEnzymesLeadComplexBiochemicalPathway InteractionsAnabolismMembraneInfectionLaboratoriesResistancePhysiology

Grant awards (64)

Repurposing antimalarials for the treatment of NTM infections$1,203,091

R01 · FY2025 · AI · contact PI

Assembly and export of mycobacterial lipoglycans$1,099,930

R01 · FY2025 · AI · contact PI

Intermembrane transport of lipids and metabolites by mycobacterial MmpL protein complexes$811,396

R01 · FY2025 · AI

Tailoring modifications of polysaccharides in Mycobacterium tuberculosis$637,594

R01 · FY2025 · AI · contact PI

Tailoring modifications of polysaccharides in Mycobacterium tuberculosis$637,594

R01 · FY2024 · AI · contact PI

MmpL3 as a target for novel anti-TB agents$628,287

R01 · FY2024 · AI · contact PI

Repurposing antimalarials for the treatment of NTM infections$118,512

R01 · FY2024 · AI · contact PI

Repurposing antimalarials for the treatment of NTM infections$666,325

R01 · FY2023 · AI · contact PI

Tailoring modifications of polysaccharides in Mycobacterium tuberculosis$637,594

R01 · FY2023 · AI · contact PI

MmpL3 as a target for novel anti-TB agents$628,287

R01 · FY2023 · AI · contact PI

Assembly and export of mycobacterial lipoglycans$600,864

R01 · FY2023 · AI · contact PI

Assembly and export of mycobacterial lipoglycans$663,504

R01 · FY2022 · AI · contact PI

Repurposing antimalarials for the treatment of NTM infections$645,166

R01 · FY2022 · AI · contact PI

Tailoring modifications of polysaccharides in Mycobacterium tuberculosis$637,594

R01 · FY2022 · AI · contact PI

MmpL3 as a target for novel anti-TB agents$628,287

R01 · FY2022 · AI · contact PI

Assembly and export of mycobacterial lipoglycans$676,504

R01 · FY2021 · AI · contact PI

MmpL3 as a target for novel anti-TB agents$630,615

R01 · FY2021 · AI · contact PI

Tailoring modifications of polysaccharides in Mycobacterium tuberculosis$511,685

R01 · FY2021 · AI · contact PI

Inhibitors of Mycobacterium tuberculosis FAS-II dehydratases$200,240

R21 · FY2021 · AI · contact PI

Adjunct therapeutic potential of a repurposed drug inhibiting Mycobacterium abscessus biofilm formation$190,000

R21 · FY2021 · AI · contact PI

MmpL3 as a target for novel anti-TB agents$669,615

R01 · FY2020 · AI · contact PI

Tailoring modifications of polysaccharides in Mycobacterium tuberculosis$667,066

R56 · FY2020 · AI · contact PI

Recombinant BCG-based SARS-CoV-2 vaccine$411,968

R21 · FY2020 · AI · contact PI

Adjunct therapeutic potential of a repurposed drug inhibiting Mycobacterium abscessus biofilm formation$228,000

R21 · FY2020 · AI · contact PI

Mycobacterium tuberculosis methylglucose lipopolysaccharides$228,000

R21 · FY2020 · AI · contact PI

Inhibitors of Mycobacterium tuberculosis FAS-II dehydratases$175,760

R21 · FY2020 · AI · contact PI

Biogenesis of Lipoarabinomannan in Mycobacteria$423,581

R01 · FY2019 · AI · contact PI

Mycobacterium tuberculosis methylglucose lipopolysaccharides$190,000

R21 · FY2019 · AI · contact PI

2019 Tuberculosis Drug Discovery and Development GRC: Shortening the Duration of Tuberculosis Chemotherapy and GRS$6,000

R13 · FY2019 · AI · contact PI

MmpL3 as a target for novel anti-TB agents$525,678

R01 · FY2018 · AI · contact PI

Biogenesis of Lipoarabinomannan in Mycobacteria$421,985

R01 · FY2018 · AI · contact PI

Mechanisms of Susceptibility and Resistance of Mycobacterium tuberculosis to Isoxyl and Thiacetazone$233,627

R21 · FY2018 · AI · contact PI

MmpL3 as a target for novel anti-TB agents$513,570

R01 · FY2017 · AI · contact PI

Biogenesis of Lipoarabinomannan in Mycobacteria$420,348

R01 · FY2017 · AI · contact PI

Mechanisms of Susceptibility and Resistance of Mycobacterium tuberculosis to Isoxyl and Thiacetazone$208,087

R21 · FY2017 · AI · contact PI

MmpL3 as a target for novel anti-TB agents$507,201

R01 · FY2016 · AI · contact PI

Biogenesis of Lipoarabinomannan in Mycobacteria$422,956

R01 · FY2016 · AI · contact PI

Mycobacterium Tuberculosis Cell Wall Assembly$226,500

R21 · FY2016 · AI · contact PI

MmpL3 as a target for novel anti-TB agents$538,629

R01 · FY2015 · AI · contact PI

Disinfectant-resistant mycobacteria$355,434

R01 · FY2015 · AI · contact PI

Mycobacterium Tuberculosis Cell Wall Assembly$187,500

R21 · FY2015 · AI · contact PI

Disinfectant-resistant mycobacteria$355,434

R01 · FY2014 · AI · contact PI

Biogenesis of lipoarabinomannan in mycobacteria$353,057

R01 · FY2014 · AI · contact PI

Biogenesis of lipoarabinomannan in mycobacteria$388,613

R01 · FY2013 · AI · contact PI

Disinfectant-resistant mycobacteria$334,109

R01 · FY2013 · AI · contact PI

Biogenesis of lipoarabinomannan in mycobacteria$413,416

R01 · FY2012 · AI · contact PI

Mode of Action of Thiorcarlide in Mycobacterium Tuberculosis$360,187

R01 · FY2012 · AI · contact PI

Disinfectant-resistant mycobacteria$353,628

R01 · FY2012 · AI · contact PI

Biogenesis of lipoarabinomannan in mycobacteria$412,073

R01 · FY2011 · AI · contact PI

Disinfectant-resistant mycobacteria$365,378

R01 · FY2011 · AI · contact PI

Mode of Action of Thiorcarlide in Mycobacterium Tuberculosis$360,187

R01 · FY2011 · AI · contact PI

Development of adamantyl ureas against MDR/XDR M.tb$478,779

RC1 · FY2010 · AI · contact PI

Biogenesis of lipoarabinomannan in mycobacteria$463,381

R01 · FY2010 · AI · contact PI

Mode of Action of Thiorcarlide in Mycobacterium Tuberculosis$363,825

R01 · FY2010 · AI · contact PI

Targeting persistent M. tuberculosis through the inhibition of its aldolase$181,913

R21 · FY2010 · AI · contact PI

Characterization of gene cluster for glycophosphoinositides of mycobacteria$73,500

R03 · FY2010 · AI · contact PI

Assay Development of M. tuberculosis class II aldolase$36,750

R21 · FY2010 · NS · contact PI

Development of adamantyl ureas against MDR/XDR M.tb$500,000

RC1 · FY2009 · AI · contact PI

Mode of Action of Thiorcarlide in Mycobacterium Tuberculosis$367,500

R01 · FY2009 · AI · contact PI

Biogenesis of lipoarabinomannan in mycobacteria$336,087

R01 · FY2009 · AI · contact PI

Targeting persistent M. tuberculosis through the inhibition of its aldolase$220,500

R21 · FY2009 · AI · contact PI

Assay Development of M. tuberculosis class II aldolase$147,000

R21 · FY2009 · NS · contact PI

Biogenesis of lipoarabinomannan in mycobacteria$326,298

R01 · FY2008 · AI · contact PI

Biogenesis of lipoarabinomannan in mycobacteria$356,936

R01 · FY2007 · AI · contact PI